Tuesday, 29 March 2011

Disease activity-free status: the new gold standard?

Could we use disease-activity free status to determine the effectiveness of new MS disease-modifying therapies? It may make it easier to do head-to-head studies.

Please see the following links:
Coles et al. Lancet Neurol. 2011 Apr;10(4):338-48.

Giovannoni et al. Lancet Neurol. 2011 Apr;10(4):329-337.

No comments:

Post a Comment

Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.